155 related articles for article (PubMed ID: 11106262)
21. Enhancement of oral bioavailability of paclitaxel after oral administration of Schisandrol B in rats.
Jin J; Bi H; Hu J; Zhong G; Zhao L; Huang Z; Huang M
Biopharm Drug Dispos; 2010 May; 31(4):264-8. PubMed ID: 20437465
[TBL] [Abstract][Full Text] [Related]
22. Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form.
Shin BS; Kim HJ; Hong SH; Lee JB; Hwang SW; Lee MH; Yoo SD
Cancer Chemother Pharmacol; 2009 Jun; 64(1):87-94. PubMed ID: 18941747
[TBL] [Abstract][Full Text] [Related]
23. Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats.
Li X; Choi JS
Int J Pharm; 2007 Jun; 337(1-2):188-93. PubMed ID: 17267149
[TBL] [Abstract][Full Text] [Related]
24. Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats.
Choi JS; Jo BW
Int J Pharm; 2004 Aug; 280(1-2):221-7. PubMed ID: 15265561
[TBL] [Abstract][Full Text] [Related]
25. Effect of interleukin-2 pretreatment on paclitaxel absorption and tissue disposition after oral and intravenous administration in mice.
Hosten B; Abbara C; Petit B; Dauvin A; Bourasset F; Farinotti R; Gonin P; Bonhomme-Faivre L
Drug Metab Dispos; 2008 Aug; 36(8):1729-35. PubMed ID: 18508881
[TBL] [Abstract][Full Text] [Related]
26. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
Bradley MO; Webb NL; Anthony FH; Devanesan P; Witman PA; Hemamalini S; Chander MC; Baker SD; He L; Horwitz SB; Swindell CS
Clin Cancer Res; 2001 Oct; 7(10):3229-38. PubMed ID: 11595719
[TBL] [Abstract][Full Text] [Related]
27. The influence of enaminones on the transport and oral bioavailability of P-glycoprotein substrate therapeutic agents.
Salama NN; Scott KR; Eddington ND
Int J Pharm; 2004 Apr; 273(1-2):135-47. PubMed ID: 15010138
[TBL] [Abstract][Full Text] [Related]
28. Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein.
Kemper EM; van Zandbergen AE; Cleypool C; Mos HA; Boogerd W; Beijnen JH; van Tellingen O
Clin Cancer Res; 2003 Jul; 9(7):2849-55. PubMed ID: 12855665
[TBL] [Abstract][Full Text] [Related]
29. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine.
Kharasch ED; Hoffer C; Whittington D; Sheffels P
Clin Pharmacol Ther; 2003 Dec; 74(6):543-54. PubMed ID: 14663457
[TBL] [Abstract][Full Text] [Related]
30. The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice.
Gallo JM; Li S; Guo P; Reed K; Ma J
Cancer Res; 2003 Aug; 63(16):5114-7. PubMed ID: 12941842
[TBL] [Abstract][Full Text] [Related]
31. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
Liu J; Kraut EH; Balcerzak S; Grever M; D'Ambrosio S; Chan KK
Cancer Chemother Pharmacol; 2002 Dec; 50(6):445-53. PubMed ID: 12451470
[TBL] [Abstract][Full Text] [Related]
32. Effects of quercetin on the pharmacokinetics of Etoposide after oral or intravenous administration of etoposide in rats.
Li X; Choi JS
Anticancer Res; 2009 Apr; 29(4):1411-5. PubMed ID: 19414395
[TBL] [Abstract][Full Text] [Related]
33. Enhanced bioavailability of etoposide after oral or intravenous administration of etoposide with kaempferol in rats.
Li C; Li X; Choi JS
Arch Pharm Res; 2009 Jan; 32(1):133-8. PubMed ID: 19183886
[TBL] [Abstract][Full Text] [Related]
34. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
Miller AA; Rosner GL; Egorin MJ; Hollis D; Lichtman SM; Ratain MJ
Clin Cancer Res; 2004 Dec; 10(24):8325-31. PubMed ID: 15623609
[TBL] [Abstract][Full Text] [Related]
35. A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application.
Veltkamp SA; Alderden-Los C; Sharma A; Rosing H; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2007 Jan; 59(1):43-50. PubMed ID: 16680462
[TBL] [Abstract][Full Text] [Related]
36. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges.
Torne SJ; Ansari KA; Vavia PR; Trotta F; Cavalli R
Drug Deliv; 2010 Aug; 17(6):419-25. PubMed ID: 20429848
[TBL] [Abstract][Full Text] [Related]
37. Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent.
Aneja R; Dhiman N; Idnani J; Awasthi A; Arora SK; Chandra R; Joshi HC
Cancer Chemother Pharmacol; 2007 Nov; 60(6):831-9. PubMed ID: 17285314
[TBL] [Abstract][Full Text] [Related]
38. Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies.
Nornoo AO; Zheng H; Lopes LB; Johnson-Restrepo B; Kannan K; Reed R
Eur J Pharm Biopharm; 2009 Feb; 71(2):310-7. PubMed ID: 18793723
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
40. The chemosensitizing potential of GF120918 is independent of the magnitude of P-glycoprotein-mediated resistance to conventional chemotherapeutic agents in a small cell lung cancer line.
Myer MS; Joone G; Chasen MR; van Rensburg CE
Oncol Rep; 1999; 6(1):217-8. PubMed ID: 9864431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
